ShockWave Medical Stock Forecast, Price & News

ShockWave Medical (NASDAQ:SWAV) Frequently Asked Questions

Is ShockWave Medical a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ShockWave Medical in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ShockWave Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SWAV, but not buy additional shares or sell existing shares.
View analyst ratings for ShockWave Medical or view top-rated stocks.

How has ShockWave Medical's stock been impacted by Coronavirus?

ShockWave Medical's stock was trading at $34.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, SWAV stock has increased by 379.5% and is now trading at $165.13.
View which stocks have been most impacted by COVID-19.

When is ShockWave Medical's next earnings date?

ShockWave Medical is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for ShockWave Medical.

How were ShockWave Medical's earnings last quarter?

ShockWave Medical, Inc. (NASDAQ:SWAV) released its earnings results on Monday, November, 8th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.07) by $0.12. The company had revenue of $65.16 million for the quarter, compared to the consensus estimate of $61.21 million. ShockWave Medical had a negative trailing twelve-month return on equity of 17.68% and a negative net margin of 21.60%. The company's quarterly revenue was up 232.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.38) earnings per share.
View ShockWave Medical's earnings history.

What guidance has ShockWave Medical issued on next quarter's earnings?

ShockWave Medical issued an update on its FY 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $227 million-$228 million, compared to the consensus revenue estimate of $223.43 million.

What price target have analysts set for SWAV?

7 equities research analysts have issued 12-month price objectives for ShockWave Medical's stock. Their forecasts range from $200.00 to $272.00. On average, they expect ShockWave Medical's share price to reach $238.33 in the next twelve months. This suggests a possible upside of 44.3% from the stock's current price.
View analysts' price targets for ShockWave Medical or view top-rated stocks among Wall Street analysts.

Who are ShockWave Medical's key executives?

ShockWave Medical's management team includes the following people:

• Douglas Evan Godshall, President, Chief Executive Officer & Director (LinkedIn Profile)
• Mike Maszy, Vice President-Operations
• Daniel Puckett, Chief Financial officer & Secretary
• Beaux Alexander, Vice President-Clinical Affairs
• W. Patrick Stephens, Vice President-Research & Development

What is Doug Godshall's approval rating as ShockWave Medical's CEO?

8 employees have rated ShockWave Medical CEO Doug Godshall on Glassdoor.com. Doug Godshall has an approval rating of 89% among ShockWave Medical's employees.

Who are some of ShockWave Medical's key competitors?

Some companies that are related to ShockWave Medical include Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Hill-Rom (HRC), Penumbra (PEN), NovoCure (NVCR), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), Merit Medical Systems (MMSI) and Beauty Health (SKIN).
View all of SWAV's competitors.

What other stocks do shareholders of ShockWave Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ShockWave Medical investors own include NVIDIA (NVDA), Walt Disney (DIS), Square (SQ), Trade Desk (TTD), salesforce.com (CRM), Roku (ROKU), PayPal (PYPL), DexCom (DXCM), Alibaba Group (BABA) and Okta (OKTA).

When did ShockWave Medical IPO?

(SWAV) raised $75 million in an initial public offering (IPO) on Thursday, March 7th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Morgan Stanley and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is ShockWave Medical's stock symbol?

ShockWave Medical trades on the NASDAQ under the ticker symbol "SWAV."

Who are ShockWave Medical's major shareholders?

ShockWave Medical's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.32%), Invesco Ltd. (3.71%), Artisan Partners Limited Partnership (2.39%), Credit Suisse AG (1.71%), Geode Capital Management LLC (1.70%) and Lord Abbett & CO. LLC (1.69%). Company insiders that own ShockWave Medical stock include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, Laura Francis and Sofinnova Capital Vii Fcpr.
View institutional ownership trends for ShockWave Medical.

Which institutional investors are selling ShockWave Medical stock?

SWAV stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Credit Suisse AG, Barclays PLC, Macquarie Group Ltd., Bellevue Group AG, Caption Management LLC, Renaissance Technologies LLC, and Artisan Partners Limited Partnership. Company insiders that have sold ShockWave Medical company stock in the last year include Antoine Papiernik, Colin Cahill, Dan Puckett, Douglas Evan Godshall, Frank T Watkins, Isaac Zacharias, Kurt F Gallo, and Laura Francis.
View insider buying and selling activity for ShockWave Medical or view top insider-selling stocks.

Which institutional investors are buying ShockWave Medical stock?

SWAV stock was purchased by a variety of institutional investors in the last quarter, including Invesco Ltd., Morgan Stanley, CastleArk Alternatives LLC, Ziegler Capital Management LLC, Pura Vida Investments LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, and Penserra Capital Management LLC.
View insider buying and selling activity for ShockWave Medical or or view top insider-buying stocks.

How do I buy shares of ShockWave Medical?

Shares of SWAV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ShockWave Medical's stock price today?

One share of SWAV stock can currently be purchased for approximately $165.13.

How much money does ShockWave Medical make?

ShockWave Medical has a market capitalization of $5.83 billion and generates $67.79 million in revenue each year. The company earns $-65.70 million in net income (profit) each year or ($1.10) on an earnings per share basis.

How many employees does ShockWave Medical have?

ShockWave Medical employs 2,019 workers across the globe.

What is ShockWave Medical's official website?

The official website for ShockWave Medical is www.shockwavemedical.com.

Where are ShockWave Medical's headquarters?

ShockWave Medical is headquartered at 5403 Betsy Ross Drive, Santa Clara CA, 95054.

How can I contact ShockWave Medical?

ShockWave Medical's mailing address is 5403 Betsy Ross Drive, Santa Clara CA, 95054. The company can be reached via phone at (510) 279-4262 or via email at [email protected].